182 related articles for article (PubMed ID: 32304723)
1. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.
Laure M; Hamza H; Koch-Heier J; Quernheim M; Müller C; Schreiber A; Müller G; Pleschka S; Ludwig S; Planz O
Antiviral Res; 2020 Jun; 178():104806. PubMed ID: 32304723
[TBL] [Abstract][Full Text] [Related]
2. The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.
Haasbach E; Müller C; Ehrhardt C; Schreiber A; Pleschka S; Ludwig S; Planz O
Antiviral Res; 2017 Jun; 142():178-184. PubMed ID: 28377100
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo.
Droebner K; Pleschka S; Ludwig S; Planz O
Antiviral Res; 2011 Nov; 92(2):195-203. PubMed ID: 21854809
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
Arch Virol; 2014 Dec; 159(12):3269-78. PubMed ID: 25078390
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.
Kumar N; Sharma NR; Ly H; Parslow TG; Liang Y
Antimicrob Agents Chemother; 2011 Dec; 55(12):5553-9. PubMed ID: 21930873
[TBL] [Abstract][Full Text] [Related]
6. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo.
Pinto R; Herold S; Cakarova L; Hoegner K; Lohmeyer J; Planz O; Pleschka S
Antiviral Res; 2011 Oct; 92(1):45-56. PubMed ID: 21641936
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Papaverine as an Antiviral Agent against Influenza Viruses and Paramyxoviruses.
Aggarwal M; Leser GP; Lamb RA
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896588
[TBL] [Abstract][Full Text] [Related]
9. Effects and mechanism of Qingke Pingchuan granules against influenza virus infection.
He L; Cao J; Xie X; Zhang Y; Zhang X; Wang H; Ma L
Arch Virol; 2024 May; 169(6):130. PubMed ID: 38807015
[TBL] [Abstract][Full Text] [Related]
10. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.
Perwitasari O; Yan X; Johnson S; White C; Brooks P; Tompkins SM; Tripp RA
Antimicrob Agents Chemother; 2013 Jan; 57(1):475-83. PubMed ID: 23129053
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
12. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.
Haasbach E; Hartmayer C; Planz O
Antiviral Res; 2013 May; 98(2):319-24. PubMed ID: 23523553
[TBL] [Abstract][Full Text] [Related]
13. The effect of P38 MAP kinase inhibition in a mouse model of influenza.
Growcott EJ; Bamba D; Galarneau JR; Leonard VHJ; Schul W; Stein D; Osborne CS
J Med Microbiol; 2018 Mar; 67(3):452-462. PubMed ID: 29458547
[TBL] [Abstract][Full Text] [Related]
14. Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf/MEK/ERK signal cascade.
Marjuki H; Yen HL; Franks J; Webster RG; Pleschka S; Hoffmann E
Virol J; 2007 Dec; 4():134. PubMed ID: 18053252
[TBL] [Abstract][Full Text] [Related]
15. Germacrone inhibits early stages of influenza virus infection.
Liao Q; Qian Z; Liu R; An L; Chen X
Antiviral Res; 2013 Dec; 100(3):578-88. PubMed ID: 24095670
[TBL] [Abstract][Full Text] [Related]
16. [In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].
Shishkina LN; Nebol'sin VE; Skarnovich MO; Kabanov AS; Sergeev AA; Erdyneeva UB; Serova OA; Demina OK; Agafonov AP; Stavskiĭ EA; Drozdov IG
Antibiot Khimioter; 2010; 55(5-6):32-5. PubMed ID: 21033472
[TBL] [Abstract][Full Text] [Related]
17. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
Smee DF; Barnard DL; Jones SM
Antiviral Res; 2016 Dec; 136():45-50. PubMed ID: 27771390
[TBL] [Abstract][Full Text] [Related]
18. The effect of rosuvastatin in a murine model of influenza A infection.
Radigan KA; Urich D; Misharin AV; Chiarella SE; Soberanes S; Gonzalez A; Perlman H; Wunderink RG; Budinger GR; Mutlu GM
PLoS One; 2012; 7(4):e35788. PubMed ID: 22536437
[TBL] [Abstract][Full Text] [Related]
19. The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
Schräder T; Dudek SE; Schreiber A; Ehrhardt C; Planz O; Ludwig S
Antiviral Res; 2018 Sep; 157():80-92. PubMed ID: 29990517
[TBL] [Abstract][Full Text] [Related]
20. Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
Gao L; Han J; Si J; Wang J; Wang H; Sun Y; Bi Y; Liu J; Cao L
Antiviral Res; 2017 Jul; 143():106-112. PubMed ID: 28232246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
